Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis. (4th May 2017)

• Record Type: Journal Article
• Authors: Hedayatfar, Alireza; Falavarjani, Khalil Ghasemi; Soheilian, Masoud; Elmi Sadr, Navid; Modarres, Mehdi; Parvaresh, Mohammad Mehdi; Naseripour, Masood; Rohani, Mohammad; Almasi, Mostafa; Chee, Soon-Phaik
• Is Part Of: Ocular immunology and inflammation. Volume 25:Number 3(2017)
• Page Start: 308
• Page End: 314
• Publication Date: 2017-05-04
• Subjects: Multiple sclerosis -- mycophenolate mofetil -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2016.1178302
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To report the efficacy of mycophenolate mofetil (MMF) as adjunctive therapy for the treatment of multiple sclerosis (MS)-associated uveitis. Methods : In this retrospective, interventional case series, patients with MS-associated uveitis who were treated by MMF as an adjunct therapy to systemic corticosteroid were studied. Patients' demographics, clinical course, response to treatment, and complications were assessed. Results : A total of 30 eyes of 15 patients with a mean age of 34.5 ± 8.3 years were studied. In three patients (20%), onset of uveitis preceded the diagnosis of MS. The course of MS was relapsing–remitting in 11 patients (73.3%) and secondary progressive in four patients (26.7%). At 1 year after institution of MMF, all the patients were on oral prednisolone ≤ 7.5 mg/day, all eyes were quiet without macular edema, and 53.3% of eyes gained visual improvement. Supplemental periocular and intraocular injections were needed during the first 6 months after starting MMF therapy. The systemic adverse effects were transient and minor in severity. Conclusions : MMF had beneficial effects on vision and intraocular inflammation with an acceptable safety profile.